EUVIMEDEUVIMED entdecken
Crossref

Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival

Elizabeth S Duke iD, Diana Bradford iD, Arup K Sinha iD, Xiaoxue Li, Pallavi S Mishra-Kalyani iD, R Angelo de Claro iD, Erin Larkins, Nicole Drezner

Journal of Clinical Oncology · 20.05.2026 · 44 (15) · 1457-1464

DOI: 10.1200/jco-25-02375 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.05.2026. Verfasst von Elizabeth S Duke und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation and Research, Silver Spring, MD. Hauptthemen laut MEDLINE: Pyridines, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overall survival (OS) should be evaluated in all randomized cancer trials, even when not the primary end point, as it is clinically meaningful and measures both safety and efficacy. Crossover from the control to experimental arms in randomized trials may be incorporated to allow access to promising investigational treatments after progression on a control arm. The results of Study LIBRETTO-431, an ex-US multiregional, open-label, randomized, active-controlled trial of selpercatinib versus platinum-based and pemetrexed chemotherapy with or without pembrolizumab in patients with treatment-naïve advanced rearranged during transfection fusion–positive non–small cell lung cancer, highlight the challenges of interpreting OS in trials with high crossover rates and variable postprogression therapies. Trial results demonstrated a large improvement in progression-free survival with an acceptable safety profile, but were accompanied by an immature OS analysis with a hazard ratio of 1.26, favoring the chemoimmunotherapy arm. Regardless of the position of OS in the end point hierarchy, it is critical that OS analyses include prespecified plans for data collection and analytical methods to account for the potential impact of postprogression therapies on the interpretation of study results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridinesLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungHumansRandomized Controlled Trials as TopicCross-Over StudiesPemetrexedProgression-Free SurvivalPyrazoles

Substanzen

PyridinesselpercatinibPemetrexedPyrazoles

Autor:innen und Institutionen

  • Center for Drug Evaluation and Research, Silver Spring, MD.
  • Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD.

ORCID-Profile: Elizabeth S Duke, Diana Bradford, Arup K Sinha, Pallavi S Mishra-Kalyani, R Angelo de Claro

Zitieren

APA

Duke, E. S., Bradford, D., Sinha, A. K., Li, X., Mishra-Kalyani, P. S., de Claro, R. A., Larkins, E., & Drezner, N. (2026). Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival. Journal of Clinical Oncology, 44(15), 1457-1464. https://doi.org/10.1200/jco-25-02375

Vancouver

Duke ES, Bradford D, Sinha AK, Li X, Mishra-Kalyani PS, de Claro RA, et al. Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival. Journal of Clinical Oncology. 2026;44(15):1457-1464. doi:10.1200/jco-25-02375

BibTeX
@article{Duke2026,
  author = {Duke, Elizabeth S and Bradford, Diana and Sinha, Arup K and Li, Xiaoxue and Mishra-Kalyani, Pallavi S and de Claro, R Angelo and Larkins, Erin and Drezner, Nicole},
  title = {Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {15},
  pages = {1457--1464},
  doi = {10.1200/jco-25-02375}
}
Kostenlos starten →